Ticker News
$COCH News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
Envoy Medical (COCH) to present at H.C. Wainwright conference on Sept. 15
Envoy Medical (COCH) said CEO Brent Lucas will present at the H.C. Wainwright 28th Annual Global Investment Conference on Sept. 15 at 2:00 PM ET; the presentation will be webcast and available on demand for 90 days. The company highlights its innovation pipeline in the release — including the investigational Acclaim fully implanted cochlear implant (FDA Breakthrough Device) and the commercial Esteem implant — so the session is a likely venue for pipeline, clinical or regulatory updates.
Envoy (COCH) says all 56 patients reached 3‐month visit in pivotal Acclaim cochlear implant trial
Envoy Medical (COCH) reported that all 56 patients enrolled in its pivotal trial of the investigational fully implanted Acclaim cochlear implant have completed their three‐month visits. The company is continuing to collect safety and other study measures for inclusion in a planned PMA submission and expects six‐month visits by late 2026 and full 12‐month follow‐up by April 2027, but did not disclose any safety or efficacy results.
Envoy Medical (COCH) terminates $15M ATM equity facility
Envoy Medical (COCH) terminated its at-the-market equity facility that allowed the company to sell up to $15.0 million of common stock, effective June 24, 2026. The company said the move reflects confidence in its current capital position, but the release gives no cash-balance or runway details and removes a ready mechanism for near-term equity raises (i.e., potential dilution). Timing: Same-day dilution is possible only if the company starts sales under the facility, and the press release does not say when that could happen.
Envoy Medical (COCH) terminates $15M ATM facility, cites confidence in capital
Envoy Medical (NASDAQ: COCH) terminated its at-the-market equity facility that had authorized up to $15.0 million of common stock sales, effective June 24, 2026, saying the move reflects confidence in its current capital position. The termination removes an immediate source of potential share issuance (reducing near-term dilution/overhang), but the company’s release also reiterates ongoing funding and regulatory risks tied to the Acclaim cochlear implant FDA pivotal trial. Timing: Same-day dilution is possible only if the company starts sales under the facility, and the press release does not say when that could happen.